Learning Objectives:

1. Become aware of novel mechanisms of actions of SGLT2 inhibitors.

2. Become aware of the changes in progression of kidney disease in diabetes.

3. Become aware of changes in guidelines and FDA labeling based on recent publications.

Session date: 
12/16/2019 - 5:00pm to 6:00pm CST
United States
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Participation

Please login or create an account to proceed.
Speaker Name: 
George L. Bakris, M.D.